ANEON BRILLIENT, LLC - THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HEREBY INTENDS TO PROCURE THE FREEDOM OF INFORMATION ACT (FOIA) SUPPORT SERVICES FOR THE FDA'S CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) THROUGH A DIRECT 8(A) AWARD OF A SINGLE, LABOR-HOUR (L

MARKET RESEARCH CENTER OF EXCELLENCE

Department of Defense

IGF::OT::IGF-PPHF-2013-ELIGIBILITY SUPPORT

SERCO INC

IGF::OT::IGF FOR OTHER FUNCTIONS

HIGHPOINT DIGITAL, INC.

IGF::OT::IGF CCIIO ENROLLMENT RESOLUTION AND RECONCILIATION, FORM 1095-A DATA REPORTING TASK ORDER

COGNOSANTE, LLC

IGF::OT::IGF ELIGIBILITY APPEALS OPERATIONS SUPPORT

MAXIMUS FEDERAL SERVICES, INC.

IGF::OT::IGF THE CERT PROGRAM CALCULATES BI-ANNUAL IMPROPER PAYMENT RATES BASED ON THE RESULTS OF THE REVIEWS CONDUCTED. THESE RATES INCLUDE AN OVERALL NATIONAL MEDICARE FFS IMPROPER PAYMENT RATE AND IMPROPER PAYMENT RATES FOR EACH CLAIM TYPE [PART A INPATIENT HOSPITAL PROSPECTIVE PAYMENT SYSTEM (PPS); PART A EXCLUDING INPATIENT HOSPITAL PPS; PART B; AND DURABLE MEDICAL EQUIPMENT, PROSTHETICS, ORTHOTICS, AND SUPPLIES (DMEPOS)]. THE CERT PROGRAM ENSURES A STATISTICALLY VALID RANDOM SAMPLE; THEREFORE, THE IMPROPER PAYMENT RATE CALCULATED FROM THIS SAMPLE IS CONSIDERED TO BE REFLECTIVE OF ALL OF CLAIMS PROCESSED BY MEDICARE FFS PROGRAM DURING THE REPORT PERIOD. CMS ALSO USES THE CERT PROGRAM TO PERFORM SPECIAL STUDIES AND SUPPLEMENTAL MEASUREMENTS TO DETERMINE THE IMPROPER PAYMENT RATES OF PARTICULAR CLAIM TYPES. CALCULATIONS OF THESE RATES FACILITATE CMS ABILITY TO TAKE APPROPRIATE CORRECTIVE ACTIONS TO REDUCE IMPROPER PAYMENTS.

EMPOWER AI, INC.